Furthermore, the discovery that WT1 cooperates with TET2 to upregulate MEG3 expression places TET2-WT1-MEG3 signaling axis as a central tumor suppressive pathway in AML, therefore emphasizing the potentials of this axis in AML diagnosis and therapy. This evidence concerns the gene TET2 and acute myeloid leukemia.